Literature DB >> 30900934

Disease-modifying therapies should be stopped in NMOSD patients in remission - No.

Dalia L Rotstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30900934     DOI： 10.1177/1352458519832249

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  2 in total

1.  Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.

Authors:  Saharat Aungsumart; Metha Apiwattanakul
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

2.  Correlation of IgH-CDR3 Immune Repertoire Diversity Test in Peripheral Blood of Neuromyelitis Spectrum Diseases.

Authors:  Zhihui Peng; Hongfei Deng
Journal:  Biomed Res Int       Date:  2022-10-10       Impact factor: 3.246
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.